The management of advanced bladder carcinoma.

Abstract

Since October 1978, 25 patients with metastatic carcinoma of the bladder have been treated with cis-platinum, doxorubicin hydrochloride and cyclophosphamide. Patient selection for this protocol was relatively strict and included only patients who had measurable parameters. All 3 drugs (60 mg./m.2 cis-platinum, 40 mg./m.2 doxorubicin hydrochloride and 400 mg./m.2 cyclophosphamide) were given as a single dose every 4 weeks. Over-all, 19 of the 23 evaluable patients (82 per cent) responded to therapy. There were 5 complete drug-induced remissions and 14 partial remissions. Generally, the treatment was tolerated well and common toxic effects were myelosuppression, nausea, vomiting and alopecia. One patient died of septicemia as a result of agranulocytosis. These promising results seem to indicate the high degree of effectiveness of this combination chemotherapy against transitional cell carcinoma of the bladder.

• Authors: K R Kedia, C Gibbons, L Persky
• Journal: The Journal of urology (J Urol) Vol. 125 Issue 5 Pg. 655-8 (May 1981) ISSN: 0022-5347 [Print] United States
• PMID: 7194923 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Doxorubicin
• Cyclophosphamide
• Cisplatin

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Carcinoma, Transitional Cell (drug therapy)
• Cisplatin (administration & dosage)
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Nausea (chemically induced)
• Urinary Bladder Neoplasms (drug therapy)
• Vomiting (chemically induced)